首页> 外国专利> MUTANT GENES RELATED TO DRUG RESISTANCE AND RELAPSE OF ACUTE LYMPHOBLASTIC LEUKAEMIA AND A USE THEREOF

MUTANT GENES RELATED TO DRUG RESISTANCE AND RELAPSE OF ACUTE LYMPHOBLASTIC LEUKAEMIA AND A USE THEREOF

机译:急性淋巴母细胞白血病与药物耐药和缓解相关的突变基因及其用途

摘要

This disclosure provides mutant genes related to drug resistance and relapse of acute lymphoblastic leukaemia (ALL) and a use thereof, treatment or prevention of drug resistance and relapse of ALL and a use thereof, a use of compound Lometrexol and related inhibitors targeting GART and AITC in prevention and treatment of drug resistance and relapse of ALL, and a kit for evaluation of the risk of drug resistance and relapse of ALL. The mutation gene is a mutant gene of PRPS1. The drug acts on enzymes in purine synthesis pathway and reduces drug resistance and relapse by decreasing the concentration of hypoxanthine. The kit comprises reagents for lysis of sample cells and an instruction, wherein the instruction comprises: (i) collection and lysis of the sample cells; (b) determination of the contents of hypoxanthine, IMP, AICAR and Inosine; (c) evaluation of the risk of the drug resistance and relapse of ALL. The invention provides a powerful technical means and support for the prevention and treatment of drug resistance and relapse of ALL.
机译:本公开提供了与急性淋巴细胞白血病(ALL)的抗药性和复发有关的突变基因及其用途,治疗或预防ALL的抗药性和复发及其用途,化合物洛美特罗和靶向GART和AITC的相关抑制剂的用途预防和治疗ALL的耐药性和复发,以及用于评估ALL的耐药性和复发风险的试剂盒。突变基因是PRPS1的突变基因。该药物作用于嘌呤合成途径中的酶,并通过降低次黄嘌呤的浓度降低耐药性和复发。该试剂盒包含用于裂解样品细胞的试剂和说明书,其中该说明书包括:(i)收集和裂解样品细胞; (b)确定次黄嘌呤,IMP,AICAR和肌苷的含量; (c)评估ALL的耐药性和复发风险。本发明为预防和治疗ALL的耐药性和复发提供了强有力的技术手段和支持。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号